What Does Patent WO2003077914A1 Reveal About Binimetinib Synthesis?
Patent WO2003077914A1, titled "PYRIMIDINE DERIVATIVES," describes a class of compounds, including binimetinib, and outlines methods for their synthesis [1]. The patent details specific synthetic routes and intermediate compounds that can be used to produce these pyrimidine derivatives, which are indicated for use in treating proliferative diseases [1].
How is Binimetinib Synthesized According to the Patent?
The patent presents various synthetic schemes. One general approach involves reacting a substituted aminopyrimidine with a suitable electrophile [1]. Specific examples within the patent illustrate the step-by-step assembly of the binimetinib molecule, often involving reactions like Suzuki coupling, nucleophilic aromatic substitution, and functional group interconversions [1]. These processes aim to construct the core pyrimidine ring and attach the necessary side chains to achieve the final binimetinib structure.
When Does the Patent for Binimetinib Synthesis Expire?
The expiration date for patent WO2003077914A1 depends on several factors, including any granted patent terms and potential extensions in different jurisdictions. Information on the specific patent status and expiry for binimetinib and related patents can be found on resources like DrugPatentWatch.com [2].
Who Developed the Synthesis Described in WO2003077914A1?
The inventors listed on patent WO2003077914A1 are associated with Array BioPharma Inc. [1]. Array BioPharma was later acquired by Pfizer Inc., which is the current marketing authorization holder for binimetinib (Mektovi) in combination with encorafenib (Braftovi) for certain types of melanoma [3][4].
What Other Patents Cover Binimetinib?
Beyond the foundational synthesis patent WO2003077914A1, binimetinib is covered by numerous other patents. These patents may relate to its formulation, manufacturing processes, methods of use for specific indications, or combination therapies. A comprehensive overview of binimetinib's patent landscape, including related intellectual property and potential challenges, is available through specialized patent databases and analysis services [2].
How does Binimetinib work?
Binimetinib is a potent and selective inhibitor of MEK1 and MEK2 (mitogen-activated protein kinase kinases) [3][5]. MEK proteins are part of the RAS/RAF/MEK/ERK signaling pathway, which plays a critical role in cell growth, proliferation, and survival [3][5]. In cancers with mutations in this pathway, such as those with BRAF mutations, the pathway is constitutively activated, driving tumor growth. By inhibiting MEK, binimetinib disrupts this signaling cascade, leading to reduced tumor cell proliferation and increased cell death [3][5].
What are the uses of Binimetinib?
Binimetinib is approved for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with encorafenib [3][4]. This combination therapy targets the mutated BRAF protein and the downstream MEK proteins, offering a dual inhibition strategy against the oncogenic signaling pathway [3][4].
What are the common side effects of Binimetinib?
Common side effects associated with binimetinib, particularly when used in combination with encorafenib, can include gastrointestinal issues like diarrhea, nausea, and vomiting, as well as fatigue, muscle pain, and skin reactions [3][4]. Other potential side effects may involve liver enzyme elevations and visual disturbances [3][4].
What are the risks associated with Binimetinib treatment?
Beyond common side effects, there are specific risks associated with binimetinib treatment. These include potential cardiac issues such as reduced ejection fraction, ocular toxicities, deep vein thrombosis, pulmonary embolism, and secondary skin malignancies [3][4]. Patients undergoing treatment are closely monitored for these potential complications [3][4].
Can biosimilars be developed for Binimetinib?
The development of biosimilars for biologic drugs is a complex process. However, binimetinib is a small molecule drug, not a biologic. For small molecule drugs, the pathway to market for generic versions typically involves demonstrating bioequivalence to the reference product, rather than the extensive clinical trials required for biosimilars. Patent expiry is a key factor that opens the door for generic competition [2].
Sources:
[1] WO2003077914A1
[2] https://drugpatentwatch.com/
[3] Mektovi Prescribing Information
[4] Braftovi Prescribing Information
[5] Array BioPharma Inc. pipeline information